Project Grant R43HL182540
Award Date 9/10/25
Completion Date 5/31/26
Dollars Obligated $350K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
- The federal Project Grant award, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a real-time, continuous monitoring platform to track cardiac troponin I (cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels alongside electrocardiogram (ECG) readings. The $127,926 award to The Leland Stanford Junior University...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $306,872 project grant to Vena Vitals Inc., a women-owned small business in Irvine, California. The grant funding supports the development of "VeriSleep", a wearable device that can provide continuous, non-invasive monitoring of cardiovascular biomarkers during sleep. The goal is to create a robust, cost-effective solution that can capture...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,153 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Safebeat RX Inc. The funding supports the development of a novel, smartwatch-enabled technology that allows patients with low-risk atrial fibrillation to safely initiate antiarrhythmic medications at home. The technology analyzes post-drug ECG data taken by patients using a machine learning algorithm and provides this information to...
- This $360,320 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop and test the first continuous electrochemical sensors for monitoring large protein and peptide analytes, such as insulin and cardiac markers. The project, titled "Aptamer Tagging with Redox Quenchers: A Critical Breakthrough in the Sensitivity of...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,895 to Ricovr Healthcare Inc. to develop a rapid, low-cost, point-of-care (POC) diagnostic platform for quantitative measurement of placental growth factor (PlGF) to predict and detect pre-eclampsia. The goal is to create an objective, affordable POC tool to improve the clinical diagnosis and monitoring of pre-eclampsia, which...
- The National Heart Lung and Blood Institute awarded a $306,101 Project Grant to Teucer Biotech, Inc. under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) on April 20, 2025. The project aims to develop a novel RT-PCR-based urinary biomarker assay that can predict the development of cardiovascular outcomes earlier and with greater accuracy than current methods such as microalbuminuria. The proposed assay would measure levels of podocyte-specific mRNA in urine samples as...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded Dynocardia, Inc. a $499,881 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to complete the verification and validation (V&V) of their production-grade Vitrack hospital device. Vitrack is a wrist-wearable, cuff-less device that utilizes proprietary optomechanical sensor and computer vision technology to provide accurate, continuous, and non-invasive blood pressure monitoring, overcoming...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...